Jason Farrar
Concepts (506)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 201 | 3.000 |
Why?
| | Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.630 |
Why?
| | Mutation | 19 | 2023 | 1318 | 1.820 |
Why?
| | Ribosomal Proteins | 9 | 2021 | 24 | 1.440 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 75 | 1.300 |
Why?
| | Critical Illness | 7 | 2025 | 310 | 1.120 |
Why?
| | Public Health | 5 | 2025 | 222 | 1.090 |
Why?
| | Wounds and Injuries | 4 | 2025 | 299 | 1.050 |
Why?
| | Humans | 103 | 2025 | 52114 | 0.900 |
Why?
| | Midazolam | 1 | 2024 | 37 | 0.880 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 18 | 0.870 |
Why?
| | Biomedical Research | 3 | 2025 | 262 | 0.870 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 70 | 0.850 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 106 | 0.830 |
Why?
| | Neurosurgical Procedures | 1 | 2024 | 134 | 0.800 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1101 | 0.780 |
Why?
| | Body Weight | 2 | 2021 | 526 | 0.750 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.720 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 12 | 0.720 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 796 | 0.690 |
Why?
| | Enoxaparin | 1 | 2021 | 31 | 0.690 |
Why?
| | Vietnam | 22 | 2020 | 44 | 0.670 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2020 | 7 | 0.660 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2020 | 45 | 0.640 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 224 | 0.630 |
Why?
| | Influenza, Human | 6 | 2018 | 85 | 0.600 |
Why?
| | Thrombosis | 1 | 2021 | 252 | 0.580 |
Why?
| | Anticoagulants | 1 | 2021 | 276 | 0.580 |
Why?
| | Dengue | 5 | 2016 | 7 | 0.530 |
Why?
| | Child, Preschool | 23 | 2021 | 4001 | 0.530 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2014 | 23 | 0.530 |
Why?
| | Female | 36 | 2025 | 28055 | 0.530 |
Why?
| | Male | 35 | 2025 | 26652 | 0.520 |
Why?
| | Adult | 24 | 2025 | 14095 | 0.500 |
Why?
| | Epidemics | 4 | 2022 | 25 | 0.470 |
Why?
| | Child | 30 | 2025 | 7147 | 0.470 |
Why?
| | GATA1 Transcription Factor | 2 | 2017 | 7 | 0.460 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 60 | 0.450 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 16 | 0.440 |
Why?
| | Infant | 18 | 2021 | 3660 | 0.440 |
Why?
| | RNA Precursors | 1 | 2014 | 9 | 0.440 |
Why?
| | Intensive Care Units | 4 | 2025 | 234 | 0.440 |
Why?
| | Codon, Initiator | 1 | 2014 | 9 | 0.430 |
Why?
| | Malaria, Falciparum | 3 | 2020 | 21 | 0.430 |
Why?
| | Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.430 |
Why?
| | Typhoid Fever | 4 | 2015 | 5 | 0.420 |
Why?
| | Point Mutation | 1 | 2014 | 67 | 0.420 |
Why?
| | Enteral Nutrition | 2 | 2025 | 153 | 0.410 |
Why?
| | Aged | 13 | 2025 | 10142 | 0.410 |
Why?
| | Middle Aged | 16 | 2025 | 13028 | 0.400 |
Why?
| | Vaccination | 6 | 2024 | 296 | 0.400 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1199 | 0.390 |
Why?
| | Science | 3 | 2021 | 21 | 0.370 |
Why?
| | Prognosis | 6 | 2024 | 2093 | 0.370 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 26 | 0.360 |
Why?
| | Mycobacterium tuberculosis | 4 | 2018 | 249 | 0.360 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2025 | 57 | 0.350 |
Why?
| | Artemisinins | 3 | 2020 | 8 | 0.350 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.350 |
Why?
| | Mycological Typing Techniques | 1 | 2010 | 3 | 0.350 |
Why?
| | Antimalarials | 3 | 2020 | 32 | 0.340 |
Why?
| | DNA, Fungal | 1 | 2010 | 43 | 0.340 |
Why?
| | Gene Deletion | 1 | 2011 | 274 | 0.330 |
Why?
| | Disease Outbreaks | 5 | 2022 | 122 | 0.330 |
Why?
| | Adolescent | 19 | 2025 | 6681 | 0.330 |
Why?
| | Evolution, Molecular | 3 | 2021 | 95 | 0.320 |
Why?
| | Antibodies, Viral | 5 | 2021 | 110 | 0.320 |
Why?
| | Salmonella typhi | 3 | 2015 | 5 | 0.310 |
Why?
| | Viruses | 3 | 2015 | 24 | 0.300 |
Why?
| | Malaria | 2 | 2020 | 37 | 0.300 |
Why?
| | Insulin, Isophane | 2 | 2025 | 2 | 0.300 |
Why?
| | Young Adult | 15 | 2025 | 4307 | 0.290 |
Why?
| | Viral Vaccines | 2 | 2020 | 16 | 0.290 |
Why?
| | Hyperglycemia | 2 | 2025 | 89 | 0.280 |
Why?
| | Influenza A Virus, H5N1 Subtype | 4 | 2016 | 7 | 0.280 |
Why?
| | Dengue Vaccines | 2 | 2018 | 2 | 0.280 |
Why?
| | Hand, Foot and Mouth Disease | 2 | 2018 | 2 | 0.270 |
Why?
| | Retrospective Studies | 7 | 2025 | 6610 | 0.270 |
Why?
| | Enterovirus | 2 | 2018 | 8 | 0.270 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2018 | 504 | 0.270 |
Why?
| | DNA Methylation | 6 | 2023 | 583 | 0.270 |
Why?
| | Information Dissemination | 2 | 2020 | 85 | 0.260 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 177 | 0.260 |
Why?
| | Dengue Virus | 2 | 2018 | 13 | 0.260 |
Why?
| | Coronavirus Infections | 2 | 2020 | 188 | 0.260 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 217 | 0.250 |
Why?
| | Prospective Studies | 6 | 2024 | 2424 | 0.250 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2016 | 36 | 0.240 |
Why?
| | Communicable Diseases, Emerging | 2 | 2015 | 13 | 0.240 |
Why?
| | Incidence | 4 | 2025 | 1070 | 0.240 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2025 | 4 | 0.230 |
Why?
| | Lipomatosis | 1 | 2025 | 6 | 0.230 |
Why?
| | Viral Load | 3 | 2021 | 80 | 0.230 |
Why?
| | Bone Marrow Diseases | 1 | 2025 | 11 | 0.230 |
Why?
| | Blood Glucose | 2 | 2025 | 475 | 0.230 |
Why?
| | Kidney Function Tests | 1 | 2025 | 55 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 411 | 0.230 |
Why?
| | Enterovirus Infections | 2 | 2015 | 7 | 0.230 |
Why?
| | Swine Diseases | 2 | 2015 | 7 | 0.230 |
Why?
| | Tuberculosis | 2 | 2018 | 131 | 0.230 |
Why?
| | Creatinine | 1 | 2025 | 158 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2016 | 81 | 0.220 |
Why?
| | Nutritional Support | 1 | 2024 | 34 | 0.220 |
Why?
| | Lymphoma | 1 | 2025 | 71 | 0.220 |
Why?
| | Central Nervous System Infections | 2 | 2014 | 7 | 0.220 |
Why?
| | Hemophilia A | 1 | 2024 | 26 | 0.210 |
Why?
| | Adaptive Immunity | 2 | 2021 | 32 | 0.210 |
Why?
| | Drug Incompatibility | 1 | 2023 | 2 | 0.210 |
Why?
| | Genotype | 6 | 2018 | 563 | 0.200 |
Why?
| | Hemorrhage | 2 | 2024 | 222 | 0.200 |
Why?
| | Neuromuscular Blockade | 1 | 2023 | 13 | 0.200 |
Why?
| | Gene Rearrangement | 1 | 2024 | 76 | 0.200 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 167 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 335 | 0.200 |
Why?
| | Osteosarcoma | 1 | 2023 | 44 | 0.200 |
Why?
| | Consensus | 1 | 2024 | 190 | 0.200 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2018 | 101 | 0.200 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 249 | 0.200 |
Why?
| | World Health Organization | 4 | 2018 | 57 | 0.200 |
Why?
| | Infection Control | 2 | 2019 | 46 | 0.190 |
Why?
| | Risk Factors | 6 | 2025 | 3922 | 0.190 |
Why?
| | Genetic Variation | 5 | 2015 | 224 | 0.190 |
Why?
| | Tuberculosis, Meningeal | 2 | 2016 | 4 | 0.190 |
Why?
| | Chromosome Aberrations | 3 | 2017 | 295 | 0.190 |
Why?
| | Azacitidine | 2 | 2023 | 39 | 0.190 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 15 | 0.180 |
Why?
| | Serum Albumin | 1 | 2022 | 57 | 0.180 |
Why?
| | Recurrence | 3 | 2022 | 680 | 0.180 |
Why?
| | Vaccines, Attenuated | 2 | 2018 | 11 | 0.180 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 49 | 0.180 |
Why?
| | Age Factors | 3 | 2021 | 1125 | 0.180 |
Why?
| | Biotechnology | 1 | 2021 | 15 | 0.180 |
Why?
| | Myelitis | 1 | 2021 | 1 | 0.180 |
Why?
| | Enterovirus D, Human | 1 | 2021 | 1 | 0.180 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 11 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 184 | 0.180 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 2 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 75 | 0.170 |
Why?
| | Plasmodium falciparum | 2 | 2020 | 23 | 0.170 |
Why?
| | Narration | 1 | 2021 | 27 | 0.170 |
Why?
| | Co-Repressor Proteins | 1 | 2021 | 18 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2021 | 51 | 0.170 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 316 | 0.170 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 34 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 111 | 0.170 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 31 | 0.170 |
Why?
| | Injury Severity Score | 1 | 2021 | 162 | 0.170 |
Why?
| | B-Lymphocytes | 1 | 2021 | 180 | 0.170 |
Why?
| | Kidney | 1 | 2025 | 713 | 0.170 |
Why?
| | Leadership | 1 | 2021 | 104 | 0.160 |
Why?
| | Chromatin | 1 | 2021 | 141 | 0.160 |
Why?
| | Leucine | 1 | 2020 | 113 | 0.160 |
Why?
| | Microbial Sensitivity Tests | 4 | 2015 | 270 | 0.160 |
Why?
| | International Cooperation | 2 | 2017 | 52 | 0.160 |
Why?
| | Bacteremia | 1 | 2020 | 89 | 0.160 |
Why?
| | Blood Transfusion | 1 | 2020 | 129 | 0.160 |
Why?
| | Molecular Sequence Data | 5 | 2015 | 766 | 0.150 |
Why?
| | MicroRNAs | 2 | 2021 | 385 | 0.150 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2016 | 14 | 0.150 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 7 | 0.150 |
Why?
| | Ribosomes | 2 | 2009 | 33 | 0.150 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 3 | 0.150 |
Why?
| | Sex Factors | 1 | 2021 | 731 | 0.150 |
Why?
| | Mosquito Control | 1 | 2018 | 4 | 0.140 |
Why?
| | Plasmodium | 1 | 2018 | 5 | 0.140 |
Why?
| | Immunization, Secondary | 1 | 2018 | 24 | 0.140 |
Why?
| | Infant, Newborn | 5 | 2023 | 2859 | 0.140 |
Why?
| | Base Sequence | 5 | 2014 | 627 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 424 | 0.140 |
Why?
| | Research Report | 1 | 2018 | 19 | 0.140 |
Why?
| | Genome, Viral | 2 | 2015 | 80 | 0.140 |
Why?
| | Influenza in Birds | 2 | 2016 | 5 | 0.140 |
Why?
| | Isoniazid | 1 | 2018 | 28 | 0.140 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2018 | 28 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2023 | 5456 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1368 | 0.140 |
Why?
| | Antitubercular Agents | 1 | 2018 | 84 | 0.140 |
Why?
| | Influenza A virus | 1 | 2017 | 16 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 64 | 0.130 |
Why?
| | Parasitemia | 1 | 2017 | 6 | 0.130 |
Why?
| | Malaria, Cerebral | 1 | 2017 | 1 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2017 | 4 | 0.130 |
Why?
| | Endemic Diseases | 1 | 2017 | 25 | 0.130 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.130 |
Why?
| | Agammaglobulinemia | 1 | 1996 | 9 | 0.130 |
Why?
| | X Chromosome | 1 | 1996 | 13 | 0.130 |
Why?
| | Protozoan Proteins | 1 | 2017 | 32 | 0.130 |
Why?
| | Genome, Human | 2 | 2021 | 121 | 0.130 |
Why?
| | Public Health Practice | 1 | 2017 | 42 | 0.130 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2016 | 8 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2024 | 1035 | 0.130 |
Why?
| | Benzoxazines | 1 | 2016 | 18 | 0.130 |
Why?
| | Phenotype | 3 | 2021 | 794 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | Disease Susceptibility | 3 | 2021 | 96 | 0.130 |
Why?
| | Animals | 13 | 2023 | 13332 | 0.130 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.120 |
Why?
| | HIV Infections | 2 | 2010 | 382 | 0.120 |
Why?
| | Anemia | 1 | 2017 | 75 | 0.120 |
Why?
| | Enterovirus A, Human | 1 | 2016 | 1 | 0.120 |
Why?
| | Cell Proliferation | 4 | 2021 | 1017 | 0.120 |
Why?
| | Neutropenia | 1 | 1996 | 113 | 0.120 |
Why?
| | Kobuvirus | 1 | 2015 | 2 | 0.120 |
Why?
| | Immunologic Factors | 2 | 2013 | 117 | 0.120 |
Why?
| | Ebola Vaccines | 1 | 2015 | 1 | 0.120 |
Why?
| | Models, Theoretical | 3 | 2021 | 182 | 0.120 |
Why?
| | Case-Control Studies | 4 | 2017 | 1193 | 0.120 |
Why?
| | Public-Private Sector Partnerships | 1 | 2015 | 8 | 0.120 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2013 | 17 | 0.120 |
Why?
| | Editorial Policies | 1 | 2015 | 14 | 0.120 |
Why?
| | Animals, Wild | 1 | 2015 | 10 | 0.120 |
Why?
| | Zoonoses | 1 | 2015 | 13 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 580 | 0.120 |
Why?
| | Picornaviridae Infections | 1 | 2015 | 22 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 117 | 0.120 |
Why?
| | Hepatitis E | 1 | 2015 | 6 | 0.120 |
Why?
| | Earthquakes | 1 | 2015 | 5 | 0.120 |
Why?
| | Emergencies | 1 | 2015 | 80 | 0.120 |
Why?
| | Biomedical Technology | 1 | 2015 | 10 | 0.120 |
Why?
| | Azithromycin | 1 | 2015 | 25 | 0.110 |
Why?
| | Salmonella enterica | 1 | 2015 | 17 | 0.110 |
Why?
| | DNA, Bacterial | 2 | 2018 | 168 | 0.110 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 14 | 0.110 |
Why?
| | Feces | 1 | 2015 | 155 | 0.110 |
Why?
| | Research Support as Topic | 1 | 2015 | 44 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2015 | 62 | 0.110 |
Why?
| | Health Care Costs | 1 | 2016 | 174 | 0.110 |
Why?
| | Viral Envelope Proteins | 1 | 2014 | 32 | 0.110 |
Why?
| | Encephalitis, Viral | 2 | 2013 | 7 | 0.110 |
Why?
| | Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.110 |
Why?
| | Registries | 1 | 2018 | 629 | 0.110 |
Why?
| | Transcription Factors | 3 | 2024 | 564 | 0.110 |
Why?
| | K562 Cells | 1 | 2014 | 41 | 0.110 |
Why?
| | Health Policy | 1 | 2015 | 160 | 0.110 |
Why?
| | Virus Diseases | 1 | 2015 | 47 | 0.110 |
Why?
| | Chromosome Mapping | 3 | 2011 | 149 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 79 | 0.110 |
Why?
| | Circoviridae | 1 | 2014 | 1 | 0.110 |
Why?
| | Circoviridae Infections | 1 | 2014 | 1 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 83 | 0.110 |
Why?
| | Leukemia, Myeloid | 1 | 2014 | 40 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 159 | 0.110 |
Why?
| | Enteroviruses, Porcine | 1 | 2013 | 1 | 0.110 |
Why?
| | Molecular Epidemiology | 2 | 2010 | 38 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2015 | 81 | 0.110 |
Why?
| | Anemia, Macrocytic | 1 | 2013 | 2 | 0.100 |
Why?
| | Prednisolone | 1 | 2013 | 56 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2010 | 236 | 0.100 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 79 | 0.100 |
Why?
| | Cohort Studies | 3 | 2018 | 1541 | 0.100 |
Why?
| | Recombination, Genetic | 1 | 2013 | 108 | 0.100 |
Why?
| | Bacteriological Techniques | 1 | 2013 | 39 | 0.100 |
Why?
| | China | 3 | 2020 | 134 | 0.100 |
Why?
| | Models, Biological | 2 | 2021 | 731 | 0.100 |
Why?
| | Phylogeny | 4 | 2015 | 229 | 0.100 |
Why?
| | Genomics | 1 | 2014 | 265 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2021 | 1135 | 0.090 |
Why?
| | Advisory Committees | 2 | 2015 | 72 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2013 | 94 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 611 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 566 | 0.090 |
Why?
| | Chromosome Deletion | 2 | 2013 | 139 | 0.090 |
Why?
| | Haploinsufficiency | 1 | 2011 | 16 | 0.090 |
Why?
| | Mosaicism | 1 | 2011 | 17 | 0.090 |
Why?
| | Genotyping Techniques | 1 | 2011 | 19 | 0.090 |
Why?
| | Blotting, Northern | 1 | 2011 | 108 | 0.090 |
Why?
| | Prevalence | 4 | 2018 | 1013 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 215 | 0.090 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 90 | 0.090 |
Why?
| | Pilot Projects | 2 | 2025 | 712 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 184 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 23 | 0.080 |
Why?
| | Cell Line | 2 | 2014 | 1018 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 37 | 0.080 |
Why?
| | Daunorubicin | 2 | 2022 | 13 | 0.080 |
Why?
| | WT1 Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Cytarabine | 2 | 2022 | 42 | 0.080 |
Why?
| | Outpatients | 2 | 2024 | 125 | 0.080 |
Why?
| | Enterobacteriaceae | 1 | 2009 | 8 | 0.080 |
Why?
| | Viral Nonstructural Proteins | 1 | 2010 | 61 | 0.080 |
Why?
| | Enterobacteriaceae Infections | 1 | 2009 | 18 | 0.080 |
Why?
| | Plasmids | 1 | 2009 | 164 | 0.080 |
Why?
| | Quinolones | 1 | 2009 | 50 | 0.070 |
Why?
| | Semliki forest virus | 1 | 2008 | 1 | 0.070 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 18 | 0.070 |
Why?
| | Seasons | 2 | 2020 | 92 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2009 | 132 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 125 | 0.070 |
Why?
| | DNA, Viral | 3 | 2015 | 138 | 0.070 |
Why?
| | Seroepidemiologic Studies | 2 | 2018 | 44 | 0.070 |
Why?
| | Pandemics | 2 | 2024 | 579 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.070 |
Why?
| | Wilms Tumor | 1 | 2007 | 18 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.070 |
Why?
| | Neuraminidase | 1 | 2007 | 4 | 0.070 |
Why?
| | Oseltamivir | 1 | 2007 | 5 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 2 | 2007 | 528 | 0.060 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 18 | 0.060 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 25 | 0.060 |
Why?
| | DNA Helicases | 1 | 2008 | 148 | 0.060 |
Why?
| | Mice | 4 | 2023 | 5877 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2021 | 670 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 136 | 0.060 |
Why?
| | Alleles | 2 | 2017 | 277 | 0.060 |
Why?
| | Quinolines | 2 | 2017 | 43 | 0.060 |
Why?
| | Treatment Failure | 2 | 2018 | 122 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 182 | 0.060 |
Why?
| | Rifampin | 2 | 2018 | 58 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2007 | 177 | 0.060 |
Why?
| | DNA | 1 | 2008 | 543 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 60 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 88 | 0.060 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 127 | 0.060 |
Why?
| | Sus scrofa | 2 | 2015 | 38 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2025 | 60 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 86 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 374 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2282 | 0.060 |
Why?
| | Transcriptome | 2 | 2017 | 363 | 0.060 |
Why?
| | Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.050 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 18 | 0.050 |
Why?
| | Factor VIII | 1 | 2024 | 23 | 0.050 |
Why?
| | Mass Screening | 2 | 2018 | 356 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.050 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 494 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2024 | 34 | 0.050 |
Why?
| | Haplotypes | 2 | 2017 | 95 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 219 | 0.050 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 182 | 0.050 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| | Uncertainty | 1 | 2023 | 44 | 0.050 |
Why?
| | Swine | 2 | 2015 | 426 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 205 | 0.050 |
Why?
| | Autoantibodies | 1 | 2024 | 120 | 0.050 |
Why?
| | Viral Proteins | 2 | 2015 | 164 | 0.050 |
Why?
| | Nepal | 2 | 2015 | 12 | 0.050 |
Why?
| | Time Factors | 2 | 2020 | 2970 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 114 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2024 | 239 | 0.050 |
Why?
| | Apoptosis | 1 | 2008 | 1117 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 185 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 73 | 0.050 |
Why?
| | Computational Biology | 1 | 2024 | 209 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 939 | 0.050 |
Why?
| | Point-of-Care Systems | 2 | 2015 | 65 | 0.050 |
Why?
| | Poultry | 2 | 2016 | 29 | 0.050 |
Why?
| | Insulin | 1 | 2024 | 484 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| | Core Binding Factor beta Subunit | 1 | 2021 | 4 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2021 | 26 | 0.050 |
Why?
| | Strategic Stockpile | 1 | 2021 | 1 | 0.050 |
Why?
| | Emigration and Immigration | 1 | 2021 | 18 | 0.050 |
Why?
| | RNA | 1 | 2022 | 169 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 1339 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 11 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 2 | 2013 | 76 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1467 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 11 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2021 | 26 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 32 | 0.040 |
Why?
| | Africa | 1 | 2020 | 11 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 585 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 96 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 59 | 0.040 |
Why?
| | Antibody-Dependent Enhancement | 1 | 2020 | 2 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 41 | 0.040 |
Why?
| | Trans-Activators | 1 | 2021 | 138 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 134 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 123 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 37 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 231 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 307 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 110 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 945 | 0.040 |
Why?
| | Truth Disclosure | 1 | 2020 | 16 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 459 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 10 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 184 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 46 | 0.040 |
Why?
| | History, 19th Century | 1 | 2019 | 23 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 152 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2019 | 44 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 58 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2020 | 112 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 95 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1418 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 871 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2021 | 188 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 809 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 665 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 597 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 90 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 399 | 0.040 |
Why?
| | Histones | 1 | 2021 | 316 | 0.040 |
Why?
| | Japan | 1 | 2018 | 38 | 0.040 |
Why?
| | Tropical Climate | 1 | 2018 | 11 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 634 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2018 | 43 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2020 | 316 | 0.040 |
Why?
| | Case Management | 1 | 2018 | 43 | 0.040 |
Why?
| | Sputum | 1 | 2018 | 64 | 0.030 |
Why?
| | United States | 2 | 2021 | 5168 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 71 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 18 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 292 | 0.030 |
Why?
| | Urban Population | 1 | 2018 | 161 | 0.030 |
Why?
| | Erythroid Cells | 1 | 2017 | 5 | 0.030 |
Why?
| | Genes, Dominant | 1 | 2017 | 21 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2017 | 18 | 0.030 |
Why?
| | Genes, X-Linked | 1 | 2017 | 7 | 0.030 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2017 | 5 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 251 | 0.030 |
Why?
| | Erythrocytes | 1 | 2017 | 70 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 98 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 134 | 0.030 |
Why?
| | Bacterial Proteins | 2 | 2010 | 337 | 0.030 |
Why?
| | Models, Genetic | 1 | 2017 | 173 | 0.030 |
Why?
| | Alkynes | 1 | 2016 | 6 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2016 | 27 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 87 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 49 | 0.030 |
Why?
| | Efficiency | 1 | 2016 | 32 | 0.030 |
Why?
| | Africa, Western | 1 | 2015 | 5 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 67 | 0.030 |
Why?
| | Disease Reservoirs | 1 | 2015 | 3 | 0.030 |
Why?
| | Access to Information | 1 | 2015 | 20 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 49 | 0.030 |
Why?
| | Immunization Programs | 1 | 2015 | 22 | 0.030 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2015 | 5 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| | Phylogeography | 1 | 2015 | 6 | 0.030 |
Why?
| | Health Priorities | 1 | 2015 | 19 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 465 | 0.030 |
Why?
| | Meteorological Concepts | 1 | 2015 | 2 | 0.030 |
Why?
| | Protein Conformation | 1 | 2015 | 177 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 95 | 0.030 |
Why?
| | Pharynx | 1 | 2015 | 31 | 0.030 |
Why?
| | Genome, Bacterial | 1 | 2015 | 56 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 78 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 267 | 0.030 |
Why?
| | Biological Assay | 1 | 2014 | 46 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 118 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 463 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 618 | 0.030 |
Why?
| | Models, Molecular | 1 | 2015 | 351 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 234 | 0.030 |
Why?
| | Malawi | 1 | 2014 | 14 | 0.030 |
Why?
| | Child Health Services | 1 | 2015 | 78 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 401 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 126 | 0.030 |
Why?
| | Placebos | 1 | 2013 | 85 | 0.030 |
Why?
| | Geography | 1 | 2014 | 65 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2014 | 120 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2013 | 65 | 0.030 |
Why?
| | Immunomodulation | 1 | 2013 | 36 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 17 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1568 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 112 | 0.020 |
Why?
| | Models, Statistical | 1 | 2014 | 231 | 0.020 |
Why?
| | Parents | 1 | 2016 | 334 | 0.020 |
Why?
| | Thalidomide | 1 | 2013 | 377 | 0.020 |
Why?
| | Virology | 1 | 2010 | 5 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 475 | 0.020 |
Why?
| | Coma | 1 | 2010 | 17 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 621 | 0.020 |
Why?
| | Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| | Flucytosine | 1 | 2010 | 13 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2010 | 2 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 23 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 663 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 37 | 0.020 |
Why?
| | Amphotericin B | 1 | 2010 | 104 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 124 | 0.020 |
Why?
| | Carrier State | 1 | 2009 | 10 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 1214 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 739 | 0.020 |
Why?
| | Alphavirus | 1 | 2008 | 1 | 0.020 |
Why?
| | Retroviridae | 1 | 2008 | 5 | 0.020 |
Why?
| | Culex | 1 | 2008 | 5 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2009 | 462 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2008 | 20 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 48 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2008 | 44 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 108 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 191 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2009 | 173 | 0.020 |
Why?
| | Pregnancy | 1 | 2015 | 2658 | 0.020 |
Why?
| | Ankyrin Repeat | 1 | 2007 | 4 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 346 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 70 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3382 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1699 | 0.020 |
Why?
| | Birds | 1 | 2007 | 13 | 0.020 |
Why?
| | Fibroblasts | 1 | 2008 | 358 | 0.020 |
Why?
| | Program Development | 1 | 2007 | 164 | 0.020 |
Why?
| | Absorption | 1 | 2005 | 22 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 182 | 0.020 |
Why?
| | Oxygen | 1 | 2008 | 333 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 60 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 110 | 0.010 |
Why?
| | Skin Diseases | 1 | 2005 | 116 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 853 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|